Department of Rheumatology, University of Paris XII, Henri Mondor Hospital, Bd de Lattre de Tassigny, Creteil 94010, France.
Arthritis Res Ther. 2011 Aug 26;13(4):124. doi: 10.1186/ar3436.
Blocking IL-1 in patients with knee osteoarthritis is an attractive strategy. Cohen and colleagues report a randomised, placebo-controlled, multiple-dose trial using a monoclonal antibody blocking IL-1 type 1 receptor. They failed to show any positive results in terms of evolution of pain for up to 12 weeks, in line with the former trials using intraarticular injections of IL-1 receptor antagonist. A trend was observed, however, in a subgroup of patients with high level of pain at baseline. Although these data may suggest cessation of IL-1 therapy in osteoarthritis, other methods such as limited intraarticular anti-IL-1 delivery should still be considered.
阻断膝关节骨关节炎患者的 IL-1 是一种有吸引力的策略。Cohen 及其同事报告了一项使用单克隆抗体阻断 IL-1 类型 1 受体的随机、安慰剂对照、多剂量试验。他们未能显示出在长达 12 周的时间内疼痛进展方面有任何积极结果,与以前使用关节内注射 IL-1 受体拮抗剂的试验一致。然而,在基线时疼痛水平较高的亚组患者中观察到一种趋势。尽管这些数据可能表明停止骨关节炎的 IL-1 治疗,但仍应考虑其他方法,如有限的关节内抗 IL-1 递送。